Exploring the impact of comorbidities and drug resistance on mortality in ICU-acquired bloodstream infections

探讨合并症和耐药性对ICU获得性血流感染死亡率的影响

阅读:1

Abstract

Hospital-acquired bloodstream infections (BSIs) seriously challenge critically ill patients. These infections in the ICU lead to significant morbidity, mortality, increased costs, and prolonged hospital stays. Therefore, the present study investigated this condition's prevalence and risk factors. This cross-sectional study was conducted on patients with neurological and nephrological issues admitted to general ICUs and trauma patients in two large hospitals in southeastern Iran. Bacteremia prevalence and mortality effects in ICU patients were analyzed from March 2020 to September 2022 during the COVID period. The results identified 127 patients with positive blood cultures, including 59 from the general ICU and 68 from the trauma ICU, yielding prevalences of 3.02% and 1.93%, respectively. The most common comorbidities included drug addiction (36.2%), chronic hypertension (35.4%), and type 2 diabetes (25.2%). Klebsiella pneumoniae was the most frequently isolated organism, followed by Staphylococcus epidermidis, Staphylococcus aureus, and Acinetobacter. The mortality rate was 93.2% in the general ICU and 60.3% in the trauma ICU. Risk factors associated with mortality included diabetes, hypertension, renal failure, drug addiction, a history of surgery in the last 30 days, ineffective experimental antibiotic treatment, and the administration of vasopressors. The prevalence of multiple drug resistance (MDR) was 33%, while Vancomycin-Resistant Enterococcus (VRE) was found in 9.4% of cases. These findings suggest that identifying and controlling risk factors associated with bacteremia in ICU patients is essential for reducing mortality.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。